Sjögren’s syndrome CP Mavragani, GE Fragoulis, HM Moutsopoulos The Autoimmune Diseases, 495-510, 2014 | 481 | 2014 |
The geoepidemiology of Sjögren's syndrome CP Mavragani, HM Moutsopoulos Autoimmunity reviews 9 (5), A305-A310, 2010 | 406 | 2010 |
A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies M Dastmalchi, C Grundtman, H Alexanderson, CP Mavragani, ... Annals of the rheumatic diseases 67 (12), 1670-1677, 2008 | 291 | 2008 |
Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis A Nezos, F Gravani, A Tassidou, EK Kapsogeorgou, M Voulgarelis, ... Journal of autoimmunity 63, 47-58, 2015 | 260 | 2015 |
Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use S Fragkioudaki, CP Mavragani, HM Moutsopoulos Medicine 95 (25), e3766, 2016 | 238 | 2016 |
Cardiovascular disease in systemic lupus erythematosus: a comprehensive update M Giannelou, CP Mavragani Journal of autoimmunity 82, 1-12, 2017 | 191 | 2017 |
Activation of the type I interferon pathway in primary Sjogren’s syndrome CP Mavragani, MK Crow Journal of autoimmunity 35 (3), 225-231, 2010 | 186 | 2010 |
Augmented interferon‐α pathway activation in patients with Sjögren's syndrome treated with etanercept CP Mavragani, TB Niewold, NM Moutsopoulos, SR Pillemer, SM Wahl, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2007 | 186 | 2007 |
Central nervous system involvement in Sjögren’s syndrome FC Soliotis, CP Mavragani, HM Moutsopoulos Annals of the rheumatic diseases 63 (6), 616-620, 2004 | 170 | 2004 |
Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease CP Mavragani, I Sagalovskiy, Q Guo, A Nezos, EK Kapsogeorgou, P Lu, ... Arthritis & rheumatology 68 (11), 2686-2696, 2016 | 168 | 2016 |
The management of Sjögren's syndrome CP Mavragani, NM Moutsopoulos, HM Moutsopoulos Nature clinical practice Rheumatology 2 (5), 252-261, 2006 | 166 | 2006 |
Sjögren's syndrome: old and new therapeutic targets CP Mavragani, HM Moutsopoulos Journal of autoimmunity 110, 102364, 2020 | 141 | 2020 |
B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome A Nezos, A Papageorgiou, G Fragoulis, D Ioakeimidis, M Koutsilieris, ... Journal of autoimmunity 51, 89-98, 2014 | 131 | 2014 |
Predicting the outcome of Sjogren’s syndrome-associated non-hodgkin’s lymphoma patients A Papageorgiou, DC Ziogas, CP Mavragani, E Zintzaras, AG Tzioufas, ... PloS one 10 (2), e0116189, 2015 | 123 | 2015 |
Conventional therapy of Sjogren’s syndrome CP Mavragani, HM Moutsopoulos Clinical reviews in allergy & immunology 32, 284-291, 2007 | 107 | 2007 |
Endocrine alterations in primary Sjogren's syndrome: an overview CP Mavragani, GE Fragoulis, HM Moutsopoulos Journal of autoimmunity 39 (4), 354-358, 2012 | 105 | 2012 |
Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon‐β/α ratios in rheumatoid arthritis patients: a post hoc … CP Mavragani, DT La, W Stohl, MK Crow Arthritis & Rheumatism: Official Journal of the American College of …, 2010 | 102 | 2010 |
Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren’s syndrome: prevalence, clinical and laboratory associations F Gravani, I Papadaki, E Antypa, A Nezos, K Masselou, D Ioakeimidis, ... Arthritis research & therapy 17, 1-13, 2015 | 100 | 2015 |
Stress, coping strategies and social support in patients with primary Sjögren’s syndrome prior to disease onset: a retrospective case–control study D Karaiskos, CP Mavragani, S Makaroni, E Zinzaras, M Voulgarelis, ... Annals of the rheumatic diseases 68 (1), 40-46, 2009 | 95 | 2009 |
Mechanisms and new strategies for primary Sjögren's syndrome CP Mavragani Annual Review of Medicine 68 (1), 331-343, 2017 | 93 | 2017 |